Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

18.220.173.236
dgid:
enl:
npi:0
-Advertisement-
-Advertisement-
Alagille Syndrome

Case report demonstrates durable response after treatment with maralixibat in ALGS

Posted on

Clinical trials of the breakthrough drug, maralixibat, for children aged 3 months and older suffering from Alagille syndrome-related pruritus have extended up to a 4-year follow-up.

A recent report highlights a case in which a patient exhibited not just the anticipated reduction in pruritus but complete resolution of the itching after treatment with maralixibat. The patient’s response demonstrated longevity, persisting for over 7 years, and resulting in the discontinuation of all other antipruritic medications.

Reference
Garcia A, Hsu E, Lin HC. Resolution of Pruritus in a Child With Alagille Syndrome Treated With Maralixibat for Seven Years: Durable Response and Discontinuation of Other Medications. JPGN Rep. 2023;4(3):e335. doi: 10.1097/PG9.0000000000000335. PMID: 37600618; PMCID: PMC10435040.

-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-